BACE1 and Alzheimer disease: Overall, the present kinetic, structural and computational docking studies pinpoint to the simplified DNP-like analogs, 1 and 2 as a new structural template for the design and optimization of lead compounds for a more effective therapeutic strategy against AD by foreseeing a dual AChE and BACE-1 inhibitory activity.